Mehta H, et al. – This article was written with the objective to figure out if early vision gains predict long–term visual outcomes in the BEVORDEX randomised clinical trial of bevacizumab or dexamethasone implants for diabetic macular oedema. The current study showed that short–term visual gain at 12 weeks was strongly correlated with long–term vision improvement independent of treatment allocation or baseline lens status. Early improvement in central macular thickness was not predictive of long–term visual outcomes.